Novel antiatherosclerotic therapies

Libby, Peter; Everett, Brendan M.

doi:10.1161/atvbaha.118.310958

Cited by 145Atherosclerosis and Cardiovascular DiseasesLipoproteins and Cardiovascular HealthInflammasome and immune disorders

Novel antiatherosclerotic therapies

Open access

Libby, Peter, Everett, Brendan M.·2019·Arteriosclerosis, Thrombosis, and Vascular Biology

DOI 10.1161/atvbaha.118.310958PMC PMC6436984

Open this paper in CoChat — free account Open PDF

Abstract

Many measures can control lipid risk factors for atherosclerosis. Yet, even with excellent control of dyslipidemia, other sources of risk remain. Hence, we must look beyond lipids to address residual risk. Lifestyle measures should form the foundation of cardiovascular risk control. Many pharmacological interventions targeting oxidation have proven disappointing. A large program tested inhibition of a LpPLA 2 (lipoprotein-associated phospholipase A 2 ), culminating in 2 large-scale clinical trials that did not meet their primary end points. A variety of antioxidants have not shown benefit in clinical trials. Numerous laboratory and clinical studies have inculpated inflammatory pathways in the pathogenesis of atherosclerotic events. The p38 MAPK (mitogen-activated protein kinase) inhibitor losmapimod and an inhibitor of a leukocyte adhesion molecule, P-selectin, did not alter adverse events in trials. Low-dose methotrexate, despite the promising observational studies, did not lower biomarkers of inflammation or alter cardiovascular outcomes in the CIRT (cardiovascular inflammation reduction trial). Four large-scale investigations underway will determine colchicine’s ability to reduce recurrent events in secondary prevention. The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) showed that an antibody that neutralizes IL (interleukin)-1β can reduce recurrent cardiovascular events in secondary prevention. The success of CANTOS points to the pathway that leads from the NLRP3 (NOD-like receptor family, pyrin domain-containing protein 3) inflammasome through IL-1β to IL-6 as an attractive target for further study and clinical development beyond lipid therapies to address the unacceptable burden of risk that remains despite our best current care in secondary prevention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/atvbaha.118.310958

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Current anti-inflammatory approaches have limitations, including immune suppression and the associated risk of sepsis.
“These trials highlighted the potential, but also the limitations of current anti-inflammatory approaches, including immune suppression and the associated risk of sepsis.4”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [4]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · see citing works
Self-citation
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · see citing works
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962 · see citing works
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,748 · see citing works
Self-citation
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · see citing works
Activation and regulation of the inflammasomes
Latz, E., Xiao, T. S., & Stutz, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3452 · Cited by 2,884 · see citing works
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849 · see citing works
A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes
Thornberry, N., Bull, H., Calaycay, J., Chapman, K., Howard, A., Kostura, M., Miller, D. K., Molineaux, S., Weidner, J., Auniņš, J., et al. (1992) · Nature · doi:10.1038/356768a0 · Cited by 2,725 · see citing works
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683 · see citing works
Self-citation
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228 · see citing works
Self-citation
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945 · see citing works
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885 · see citing works
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Manson, J. E., Cook, N. R., Lee, I.-M. M., Christen, W., Bassuk, S. S., Mora, S., Luttmann‐Gibson, H., Gordon, D., Copeland, T., D’Agostino, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809944 · Cited by 1,646 · see citing works
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536 · see citing works
Antiinflammatory Properties of HDL
Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394 · see citing works
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233 · see citing works
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146 · see citing works
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093 · see citing works
Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,059 · see citing works
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · see citing works
Colchicine—Update on mechanisms of action and therapeutic uses
Leung, Y. Y., Hui, L., & Kraus, V. B. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.06.013 · Cited by 967 · see citing works
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T. Y., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 924 · see citing works
Self-citation
Thrombosis: tangled up in NETs
Martinod, K., & Wagner, D. D. (2013) · Blood · doi:10.1182/blood-2013-10-463646 · Cited by 875 · see citing works
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823 · see citing works
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799 · see citing works
Self-citation
Association of an intensive lifestyle intervention with remission of type 2 diabetes
Gregg, E. W., Chen, H., Wagenknecht, L. E., Clark, J. M., Delahanty, L. M., Bantle, J., Pownall, H. J., Johnson, K. C., Safford, M. M., Kitabchi, A. E., et al. (2012) · JAMA · doi:10.1001/jama.2012.67929 · Cited by 752 · see citing works
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose‐John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683 · see citing works
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 629 · see citing works
Self-citation
A Randomized Trial of Colchicine for Acute Pericarditis
Imazio, M., Brucato, A., Cemin, R., Ferrua, S., Maggiolini, S., Beqaraj, F., Demarie, D., Forno, D., Ferro, S., Maestroni, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208536 · Cited by 611 · see citing works
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
The STABILITY Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315878 · Cited by 579 · see citing works
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Ridker, P. M., Libby, P., MacFadyen, J. G., Thuren, T. Y., Ballantyne, C. M., Fonseca, F. A. H., Köenig, W., Shimokawa, H., Everett, B. M., & Glynn, R. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy310 · Cited by 556 · see citing works
Self-citation
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Wolach, O., Sellar, R. S., Martinod, K., Cherpokova, D., McConkey, M., Chappell, R. J., Silver, A. J., Adams, D., Castellano, C. A., Schneider, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8292 · Cited by 481 · see citing works
Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure
Dorsheimer, L., Assmus, B., Rasper, T., Ortmann, C. A., Ecke, A., Abou-El-Ardat, K., Schmid, T., Brüne, B., Wagner, S., Serve, H., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.3965 · Cited by 470 · see citing works
Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.149 · Cited by 465 · see citing works
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460 · see citing works
Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome: The SOLID-TIMI 52 Randomized Clinical Trial
O’Donoghue, M. L., Braunwald, E., White, H. D., Steen, D. P., Lukas, M. A., Tarka, E., Steg, P. G., Hochman, J. S., Bode, C., Maggioni, A. P., et al. (2014) · JAMA · doi:10.1001/jama.2014.11061 · Cited by 456 · see citing works
The LDL modification hypothesis of atherogenesis: an update
Steinberg, D. H. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800087-jlr200 · Cited by 452 · see citing works
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions
Raggi, P., Genest, J. J., Giles, J. T., Rayner, K. J., Dwivedi, G., Beanlands, R. S., & Gupta, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.014 · Cited by 434 · see citing works
Mechanisms of action of methotrexate
Genestier, L., Paillot, R., Quéméneur, L., Izeradjene, K., & Revillard, J. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00189-2 · Cited by 422 · see citing works
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
Wilensky, R. L., Shi, Y., Mohler, E. R., Hamamdzic, D., Burgert, M. E., Li, J., Postle, A. D., Fenning, R. S., Bollinger, J. G., Hoffman, B. E., et al. (2008) · Nature Medicine · doi:10.1038/nm.1870 · Cited by 387 · see citing works
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers
Brown, P. M., Pratt, A. G., & Isaacs, J. D. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.175 · Cited by 382 · see citing works
Novel Inflammatory Markers of Coronary Risk
Libby, P., & Ridker, P. M. (1999) · Circulation · doi:10.1161/01.cir.100.11.1148 · Cited by 375 · see citing works
Self-citation
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319 · see citing works
Self-citation
Fatty acid–induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis
Freigang, S., Ampenberger, F., Weiss, A., Kanneganti, T., Iwakura, Y., Hersberger, M., & Köpf, M. (2013) · Nature Immunology · doi:10.1038/ni.2704 · Cited by 304 · see citing works
Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome
Vaidya, K., Arnott, C. G., Martínez, G. J., Ng, B., McCormack, S. R., SULLIVAN, D. R., Celermajer, D. S., & Patel, S. (2017) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2017.08.013 · Cited by 302 · see citing works
B Cells and Humoral Immunity in Atherosclerosis
Tsiantoulas, D., Diehl, C. J., Witztum, J. L., & Binder, C. J. (2014) · Circulation Research · doi:10.1161/circresaha.113.301145 · Cited by 297 · see citing works
Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome
Martínez, G. J., Robertson, S. E. J., Barraclough, J., Xia, Q., Mallat, Z., Bursill, C. A., Celermajer, D. S., & Patel, S. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002128 · Cited by 285 · see citing works
Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)
Ridker, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03404.x · Cited by 269 · see citing works
Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development
Savchenko, A. S., Martinod, K., Seidman, M. A., Wong, S. L., Borissoff, J. I., Piazza, G., Libby, P., Goldhaber, S. Z., Mitchell, R. N., & Wagner, D. D. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12571 · Cited by 268 · see citing works
Self-citation
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial
O’Donoghue, M. L., Glaser, R., Cavender, M. A., Aylward, P. E., Bonaca, M. P., Budaj, A., Davies, R. Y., Dellborg, M., Fox, K. A. A., Gutierrez, J. A. T., et al. (2016) · JAMA · doi:10.1001/jama.2016.3609 · Cited by 249 · see citing works
Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice
Schuett, H., Oestreich, R., Waetzig, G. H., Annema, W., Luchtefeld, M., Hillmer, A., Bavendiek, U., von Felden, J., Divchev, D., Kempf, T., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.229435 · Cited by 243 · see citing works
Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non–ST-Segment Elevation Myocardial Infarction
Tardif, J., Tanguay, J., Wright, S. R., Duchatelle, V., Petroni, T., Grégoire, J. C., Ibrahim, R., Heinonen, T. M., Robb, S., Bertrand, O. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.003 · Cited by 206 · see citing works
NLRP3 inflammasome pathways in atherosclerosis
Baldrighi, M., Mallat, Z., & Li, X. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.027 · Cited by 202 · see citing works
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial
Tardif, J., McMurray, J. J. V., Klug, E., Small, R., Schumi, J., Choi, J., Cooper, J., Scott, R. C., Lewis, E. F., L’Allier, P. L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60763-1 · Cited by 199 · see citing works
Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?
Bjelakovic, G., Nikolova, D., & Gluud, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074558 · Cited by 183 · see citing works
Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk
Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.082 · Cited by 176 · see citing works
Boosting Inflammation Resolution in Atherosclerosis
Fredman, G., & Tabas, I. A. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.018 · Cited by 173 · see citing works
Methotrexate Is a JAK/STAT Pathway Inhibitor
Thomas, S. J., Fisher, K. H., Snowden, J. A., Danson, S. J., Brown, S., & Zeidler, M. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130078 · Cited by 169 · see citing works
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial
Newby, L. K., Marber, M. S., Melloni, C., Sarov‐Blat, L., Aberle, L. H., Aylward, P. E., Cai, G., de Winter, R. J., Hamm, C. W., Heitner, J. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60417-7 · Cited by 157 · see citing works
Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis
Elkhawad, M., Rudd, J. H. F., Sarov‐Blat, L., Cai, G., Wells, R., Davies, C., Collier, D., Marber, M. S., Choudhury, R. P., Fayad, Z. A., et al. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2012.02.016 · Cited by 152 · see citing works
Inflammation and Atherosclerosis
Hansson, G. K. (2017) · Circulation · doi:10.1161/circulationaha.117.030484 · Cited by 149 · see citing works
Functions of vascular wall cells related to development of transplantation-associated coronary arteriosclerosis.
Libby, P., Salomon, R., Payne, D. D., Schöen, F. J., & Pober, J. S. (1989) · PubMed · Cited by 141 · see citing works
Self-citation
Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena
Costantino, S., Libby, P., Kishore, R., Tardif, J., El‐Osta, A., & Paneni, F. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx568 · Cited by 128 · see citing works
Self-citation
Lipoprotein-associated phospholipase A2 and atherosclerosis
Wilensky, R. L., & Macphee, C. H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283307c16 · Cited by 121 · see citing works
Antioxidant Supplements to Prevent Mortality
Bjelaković, G., Nikolova, D., & Gluud, C. N. (2013) · JAMA · doi:10.1001/jama.2013.277028 · Cited by 115 · see citing works
Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome
Gallone, G., Baldetti, L., Pagnesi, M., Latib, A., Colombo, A., Libby, P., & Giannini, F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.052 · Cited by 104 · see citing works
Self-citation
New Insights from Studies of Clonal Hematopoiesis
Gibson, C. J., & Steensma, D. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3044 · Cited by 94 · see citing works
Vaccine against arteriosclerosis: an update
Chyu, K., Dimayuga, P. C., & Shah, P. K. (2017) · Therapeutic Advances in Vaccines · doi:10.1177/2051013617693753 · Cited by 90 · see citing works
Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease
Fisk, M., Gajendragadkar, P. R., Maki-Petaja, K. M., Wilkinson, I. B., & Cheriyan, J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0063-6 · Cited by 84 · see citing works
Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial
Stähli, B. E., Gebhard, C., Duchatelle, V., Cournoyer, D., Petroni, T., Tanguay, J., Robb, S., Mann, J., Guertin, M., Wright, R. S., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004255 · Cited by 81 · see citing works
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer
Hong, D. S., Jankú, F., Naing, A., Falchook, G. S., Piha-Paul, S. A., Wheler, J. J., Fu, S., Tsimberidou, A. M., Stecher, M., Mohanty, P., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0226-6 · Cited by 72 · see citing works
IL-1 signaling in atherosclerosis: sibling rivalry
Sheedy, F. J., & Moore, K. J. (2013) · Nature Immunology · doi:10.1038/ni.2711 · Cited by 64 · see citing works
Mechanisms of action of methotrexate.
Chan, E. S. L., & Cronstein, B. N. (2013) · PubMed · Cited by 62 · see citing works
Vaccination against T‐cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis
Gisterå, A., Hermansson, A., Strodthoff, D., Klement, M. L., Hedin, U., Fredrikson, G. N., Nilsson, J. Å., Hansson, G. K., & Ketelhuth, D. F. J. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12589 · Cited by 57 · see citing works
Longitudinal and secular trends in total cholesterol levels and impact of lipid-lowering drug use among Norwegian women and men born in 1905–1977 in the population-based Tromsø Study 1979–2016
Hopstock, L. A., Bønaa, K. H., Eggen, A. E., Grimsgaard, S., Jacobsen, B. K., Løchen, M., Mathiesen, E. B., Njølstad, I., & Wilsgaard, T. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015001 · Cited by 54 · see citing works
Immune-mediated mechanisms of atherosclerosis and implications for the clinic
Nus, M., & Mallat, Z. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1195686 · Cited by 44 · see citing works
A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization
Sayed, H. F. E., Kerensky, R. A., Stecher, M., Mohanty, P., & Davies, M. G. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.08.069 · Cited by 43 · see citing works
Interleukin-6 “Trans-Signaling” and Ischemic Vascular Disease: The Important Role of Soluble gp130
Morieri, M., Passaro, A., & Zuliani, G. (2017) · Mediators of Inflammation · doi:10.1155/2017/1396398 · Cited by 41 · see citing works
Vitamin D Does Not Prevent Cancer or Cardiovascular Disease: The VITAL Trial
Tice, J. A., Halalau, A., & BURKE, H. B. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05648-x · Cited by 36 · see citing works
Moving Targets
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 34 · see citing works
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial
O’Donoghue, M. L., Glaser, R., Aylward, P. E., Cavender, M. A., Crisp, A., Fox, K. A. A., Laws, I., López-Sendón, J. L., Steg, P. G., Théroux, P., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.012 · Cited by 33 · see citing works
Twenty‐Five Year Secular Trends in Lipids and Modifiable Risk Factors in a Population‐Based Biracial Cohort: The Coronary Artery Risk Development in Young Adults (CARDIA) Study, 1985–2011
Schreiner, P. J., Jacobs, D. R., Wong, N. D., & Kiefe, C. I. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003384 · Cited by 21 · see citing works
Vaccination to Prevent Cardiovascular Disease
Wolf, D., Gerhardt, T., & Ley, K. F. (2017) · Cardiac and vascular biology · doi:10.1007/978-3-319-66224-4_3 · Cited by 5 · see citing works

Flagged first, then by citations

Sorted by citations

The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873 · see citing works
Self-citation
NAFLD and cardiovascular diseases: a clinical review
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01709-7 · Cited by 670 · see citing works
Targeting cardiovascular inflammation: next steps in clinical translation
Lawler, P. R., Bhatt, D. L., Godoy, L. C., Lüscher, T. F., Bonow, R. O., Verma, S., & Ridker, P. M. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa099 · Cited by 445 · see citing works
Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke
Endres, M., Moro, M. Á., Nolte, C. H., Dames, C., Buckwalter, M. S., & Meisel, A. (2022) · Circulation Research · doi:10.1161/circresaha.121.319994 · Cited by 347 · see citing works
Inflammation in Atherosclerosis—No Longer a Theory
Libby, P. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa275 · Cited by 320 · see citing works
Self-citation
Endothelin: 30 Years From Discovery to Therapy
Barton, M., & Yanagisawa, M. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12105 · Cited by 304 · see citing works
Regulatory T Cells License Macrophage Pro-Resolving Functions During Atherosclerosis Regression
Sharma, M., Schlegel, M., Afonso, M., Brown, E. J., Rahman, K., Weinstock, A., Sansbury, B. E., Corr, E. M., van Solingen, C., Koelwyn, G., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.316461 · Cited by 231 · see citing works
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188 · see citing works
Oxidative Stress and Antioxidants in Atherosclerosis Development and Treatment
Poznyak, A. V., Grechko, A. V., Orekhova, V. A., Chegodaev, Y. S., Wu, W., & Orekhov, A. N. (2020) · Biology · doi:10.3390/biology9030060 · Cited by 152 · see citing works
High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation
Lechner, K., McKenzie, A. L., Kränkel, N., von Schacky, C., Worm, N., Nixdorff, U., Lechner, B., Scherr, J., Weingärtner, O., & Krauss, R. M. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0115 · Cited by 141 · see citing works
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics
He, L., Zhang, C., Chen, Q., Wang, L., & Huang, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108152 · Cited by 137 · see citing works
There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness
Makover, M. E., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100371 · Cited by 133 · see citing works
The Mechanism of Acrylamide-Induced Neurotoxicity: Current Status and Future Perspectives
Zhao, M., Zhang, B., & Deng, L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.859189 · Cited by 114 · see citing works
Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis
Hettwer, J., Hinterdobler, J., Miritsch, B., Deutsch, M.-A., Li, X., Mauersberger, C., Moggio, A., Braster, Q., Gram, H., Robertson, A. A. B., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab337 · Cited by 111 · see citing works
Self-citation
Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
Hetherington, I., & Totary-Jain, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.024 · Cited by 116 · see citing works
Through the layers: how macrophages drive atherosclerosis across the vessel wall
Susser, L. I., & Rayner, K. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157011 · Cited by 99 · see citing works
Interplay Between Reactive Oxygen/Reactive Nitrogen Species and Metabolism in Vascular Biology and Disease
Ushio‐Fukai, M., Ash, D., Nagarkoti, S., de Chantemèle, E. J. B., Fulton, D. J., & Fukai, T. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8161 · Cited by 96 · see citing works
Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging
Barbu, E., Popescu, M.-R., Popescu, A.-C., & Balanescu, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020963 · Cited by 91 · see citing works
Thromboinflammation: From Atherosclerosis to COVID-19
Wagner, D. D., & Heger, L. A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317162 · Cited by 88 · see citing works
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Martin, A., Lang, S., Goeser, T., Demir, M., Steffen, H., & Kasper, P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01028-4 · Cited by 90 · see citing works
The Future of Cardiovascular Stents: Bioresorbable and Integrated Biosensor Technology
Hoare, D., Bussooa, A., Neale, S. L., Mirzai, N., & Mercer, J. R. (2019) · Advanced Science · doi:10.1002/advs.201900856 · Cited by 80 · see citing works
Pathophysiological Mechanisms of Diabetes-Induced Macrovascular and Microvascular Complications: The Role of Oxidative Stress
Roy, B. (2025) · Medical Sciences · doi:10.3390/medsci13030087 · Cited by 89 · see citing works
Cyclodextrins: Potential therapeutics against atherosclerosis
Mahjoubin‐Tehran, M., Kovanen, P. T., Xu, S., Jamialahmadi, T., & Sahebkar, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107620 · Cited by 77 · see citing works
INKILN is a Novel Long Noncoding RNA Promoting Vascular Smooth Muscle Inflammation via Scaffolding MKL1 and USP10
Zhang, W., Zhao, J., Deng, L., Ishimwe, N., Pauli, J., Wu, W., Shan, S., Kempf, W., Ballantyne, M. D., Kim, D. S., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.063760 · Cited by 69 · see citing works
Anti‐inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy
Li, Y., Zhang, Y., Lu, J., Yin, Y., Xie, J., & Xu, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16798 · Cited by 67 · see citing works
Activation of Nrf2 inhibits atherosclerosis in ApoE mice through suppressing endothelial cell inflammation and lipid peroxidation
He, L., Chen, Q., Wang, L., Pu, Y., Huang, J., Cheng, C. K., Luo, J., Kang, L., Lin, X., Li, X., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103229 · Cited by 67 · see citing works
Role of pyroptosis in atherosclerosis and its therapeutic implications
He, B., Nie, Q., Wang, F., Han, Y., Yang, B., Sun, M., Fan, X., Ye, Z., Liu, P., & Wen, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30366 · Cited by 65 · see citing works
CCL4 Inhibition in Atherosclerosis: Effects on Plaque Stability, Endothelial Cell Adhesiveness, and Macrophages Activation
Chang, T., Yang, H. C., Chen, C., & Chen, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186567 · Cited by 60 · see citing works
Inflammatory Cell Recruitment in Cardiovascular Disease
Marchini, T., Mitre, L. S., & Wolf, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.635527 · Cited by 62 · see citing works
The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease
Zhou, Y., Little, P. J., Downey, L., Afroz, R., Wu, Y., Ta, H. T., Xu, S., & Kamato, D. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00100 · Cited by 59 · see citing works
Proinflammatory Mediators, IL (Interleukin)-1β, TNF (Tumor Necrosis Factor) α, and Thrombin Directly Induce Capillary Tube Regression
Koller, G. M., Schafer, C. M., Kemp, S. S., Aguera, K. N., Lin, P. K., Forgy, J. C., Griffin, C. T., & Davis, G. E. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313536 · Cited by 57 · see citing works
Inflammasomes in the Pathophysiology of Aortic Disease
Wortmann, M., Peters, A. S., Erhart, P., Körfer, D., Böckler, D., & Dihlmann, S. (2021) · Cells · doi:10.3390/cells10092433 · Cited by 56 · see citing works
Vascular endothelial cell injury: causes, molecular mechanisms, and treatments
Xia, T., Yu, J., Du, M., Chen, X., Wang, C., & Li, R. (2025) · MedComm · doi:10.1002/mco2.70057 · Cited by 51 · see citing works
Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients
Sabbatino, F., Conti, V., Liguori, L., Polcaro, G., Corbi, G., Manzo, V., Tortora, V., Carlomagno, C., Vecchione, C., Filippelli, A., et al. (2021) · Life · doi:10.3390/life11020105 · Cited by 50 · see citing works
Anti-inflammatory activity of the Tongmai Yangxin pill in the treatment of coronary heart disease is associated with estrogen receptor and NF-κB signaling pathway
Fan, Y., Liu, J., Miao, J., Zhang, X., Yan, Y., Bai, L., Chang, J., Wang, Y., Wang, L., Bian, Y., et al. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114106 · Cited by 50 · see citing works
Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
Kornmueller, K., Vidaković, I., & Prassl, R. (2019) · Molecules · doi:10.3390/molecules24152829 · Cited by 48 · see citing works
Monocytes in Uremia
Girndt, M., Trojanowicz, B., & Ulrich, C. (2020) · Toxins · doi:10.3390/toxins12050340 · Cited by 46 · see citing works
Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm
Castiglione, M. A., Jiang, Y., Mazzeo, C., Lee, S., Chen, J., Kaushansky, K., Yin, W., Lin, R. Z., Zheng, H., & Zhan, H. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15095 · Cited by 45 · see citing works
Low-dose i nterleukin 2 for the reduction of v ascular inflammati o n in acute corona ry syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial
Sriranjan, R., Zhao, T. X., Tarkin, J. M., Hubsch, A., Helmy, J., Vamvaka, E., Jalaludeen, N., Bond, S. J., Hoole, S. P., Knott, P., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062602 · Cited by 44 · see citing works
Evolving concepts in the pathophysiology of atherosclerosis: from endothelial dysfunction to thrombus formation through multiple shades of inflammation
Cimmino, G., Muscoli, S., Rosa, S. D., Cesaro, A., Perrone, M. A., Selvaggio, S., Selvaggio, G., Aimo, A., Pedrinelli, R., Mercuro, G., et al. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001450 · Cited by 45 · see citing works
The involvement of oxidative stress, neuronal lesions, neurotransmission impairment, and neuroinflammation in acrylamide-induced neurotoxicity in C57/BL6 mice
Zhao, M., Deng, L., Lu, X., Fan, L., Zhu, Y., & Zhao, L. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-18146-2 · Cited by 41 · see citing works
Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter
Chiriac, S. A., Stanciu, C., Gîrleanu, I., Cojocariu, C., Sfarti, C. V., Sîngeap, A.-M., Cuciureanu, T., Huiban, L., Muzica, C. M., Zenovia, S., et al. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/6696857 · Cited by 41 · see citing works
Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis
Jin, F., Li, J., Guo, J., Doeppner, T. R., Hermann, D. M., Yao, G., & Dai, Y. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab022 · Cited by 41 · see citing works
Pathobiology of cardiovascular diseases: an update
Buja, L. M., Giulia Ottaviani, M., & Mitchell, R. N. (2019) · Cardiovascular Pathology · doi:10.1016/j.carpath.2019.06.002 · Cited by 36 · see citing works
The Targeting of Native Proteins to the Endoplasmic Reticulum-Associated Degradation (ERAD) Pathway: An Expanding Repertoire of Regulated Substrates
Kumari, D., & Brodsky, J. L. (2021) · Biomolecules · doi:10.3390/biom11081185 · Cited by 34 · see citing works
The Mediterranean Diet And Cardioprotection: Historical Overview And Current Research
Minelli, P., & Montinari, M. R. (2019) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s219875 · Cited by 35 · see citing works
Theories and Molecular Basis of Vascular Aging: A Review of the Literature from VascAgeNet Group on Pathophysiological Mechanisms of Vascular Aging
Gkaliagkousi, Ε., Lazaridis, A. A., Doğan, S., Fraenkel, E., Tuna, B. G., Mozos, I. M., VUKIĆEVIĆ, M., Yalçın, Ö., & Gopčević, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158672 · Cited by 35 · see citing works
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
Josloff, K., Beiriger, J., Khan, A., Gawel, R. J., Kirby, R. S., Kendrick, A. D., Rao, A. K., Wang, R. X., Schafer, M., Pearce, M. E., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120419 · Cited by 34 · see citing works
Triggering receptor expressed on myeloid cells-1 (TREM-1) inhibition in atherosclerosis
Panagopoulos, A. N., Samant, S., Bakhos, J. J., Liu, M., Khan, B. A., Makadia, J., Muhammad, F., Kievit, F. M., Agrawal, D. K., & Chatzizisis, Y. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108182 · Cited by 31 · see citing works
Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy
Cen, X., Wang, B., Liang, Y., Chen, Y., Xiao, Y., Du, S., Nandakumar, K. S., Yin, H. H., Liu, S., & Cheng, K. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.001 · Cited by 30 · see citing works
Decoding microRNA drivers in atherosclerosis
Vartak, T., Kumaresan, S., & Brennan, E. (2022) · Bioscience Reports · doi:10.1042/bsr20212355 · Cited by 20 · see citing works
Antiatherosclerotic effect of dehydrocorydaline on ApoE−/− mice: inhibition of macrophage inflammation
Wen, B., Dang, Y., Wu, S., Huang, Y.-M., Ma, K., Xu, Y., Zheng, X., & Dai, X.-Y. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00769-3 · Cited by 29 · see citing works
RNA-binding proteins in vascular inflammation and atherosclerosis
Sachse, M., Tual-Chalot, S., Ciliberti, G., Amponsah-Offeh, M., Stamatelopoulos, K., Gatsiou, A., & Stellos, K. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.008 · Cited by 29 · see citing works
A Macrophage Membrane‐Functionalized, Reactive Oxygen Species‐Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management
Qu, K., Zhong, Y., Zhu, L., Mou, N., Cao, Y., Liu, J., Wu, S., Yan, M., Yan, F., Li, J., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401113 · Cited by 27 · see citing works
What constitutes an appropriate empirical trial of antianginal therapy in patients with stable angina before referral for revascularisation?
Boden, W. E., Kaski, J. C., Al-Lamee, R. K., & Weintraub, W. S. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02045-6 · Cited by 24 · see citing works
Long non-coding RNAs at the crossroad of vascular smooth muscle cell phenotypic modulation in atherosclerosis and neointimal formation
Fasolo, F., Paloschi, V., & Mäegdefessel, L. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.11.021 · Cited by 24 · see citing works
Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results
Vavere, A. L., Sinsakul, M. V., Ongstad, E. L., Yang, Y., Varma, V., Jones, C., Goodman, J., Dubois, V. F. S., Quartino, A. L., Karathanasis, S. K., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027540 · Cited by 23 · see citing works
Cardiovascular Disease Prevention: The Earlier the Better? A Review of Plant Sterol Metabolism and Implications of Childhood Supplementation
Scolaro, B., de Andrade, L. F. S., & de Castro, I. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010128 · Cited by 23 · see citing works
Ex vivo Ikkβ ablation rescues the immunopotency of mesenchymal stromal cells from diabetics with advanced atherosclerosis
Mancini, Ö. K., Huynh, D. N., Ménard, L., Tim, D. S., Ong, H., Marleau, S., Colmegna, I., & Servant, M. J. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa118 · Cited by 20 · see citing works
Therapeutic Response of miR-145 Micelles on Patient-Derived Vascular Smooth Muscle Cells
Patel, N., Chin, D. D., Magee, G. A., & Chung, E. J. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.836579 · Cited by 20 · see citing works
Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990–2022
Zhang, J., Ji, C., Zhai, X., Tong, H., & Hu, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1038738 · Cited by 20 · see citing works
MiR-135a-5p inhibits vascular smooth muscle cells proliferation and migration by inactivating FOXO1 and JAK2 signaling pathway
Li, D., & An, Y. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153091 · Cited by 20 · see citing works
Interstitial Fluid Shear Stress Induces the Synthetic Phenotype Switching of VSMCs to Release Pro-calcified Extracellular Vesicles via EGFR-MAPK-KLF5 Pathway
Gao, W., Gu, K., Ma, L., Yang, F., Deng, L., Zhang, Y., Miao, M. Z., Li, W., Li, G., Qian, H., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.90725 · Cited by 19 · see citing works
Reproduction and longevity: A Mendelian randomization study of gonadotropin-releasing hormone and ischemic heart disease
Schooling, C. M., & Ng, J. C. M. (2019) · SSM - Population Health · doi:10.1016/j.ssmph.2019.100411 · Cited by 19 · see citing works
Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease.
Garbuzenko, D. V. (2022) · Gastroenterology and hepatology from bed to bench. · doi:10.22037/ghfbb.v15i3.2549 · Cited by 19 · see citing works
Cross-Talk Between Neutrophils and Macrophages Post-Myocardial Infarction: From Inflammatory Drivers to Therapeutic Targets
Ciortan, L., Macarie, R. D., Barbu, E., Naie, M. L., Mihaila, A. C., Serbanescu, M. A., & Butoi, E. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110575 · Cited by 20 · see citing works
Trib1 Deficiency Promotes Hyperlipidemia, Inflammation, and Atherosclerosis in LDL Receptor Knockout Mice
Arndt, L., Hernández‐Reséndiz, I., Moos, D., Dokas, J., Müller, S., Jeromin, F., Wagner, R., Ceglarek, U., Heid, I. M., Höring, M., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318137 · Cited by 18 · see citing works
Indoxyl sulfate promotes the atherosclerosis through up-regulating the miR-34a expression in endothelial cells and vascular smooth muscle cells in vitro
Li, X., Lu, Z., Zhou, F., Jin, W., Yang, Y., Chen, S., Xie, Z., & Zhao, Y. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106763 · Cited by 18 · see citing works
Immune-Inflammation in Atherosclerosis: A New Twist in an Old Tale
Talepoor, A. G., Fouladseresht, H., Khosropanah, S., & Doroudchi, M. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666191016095725 · Cited by 16 · see citing works
Common cytokine receptor gamma chain family cytokines activate MAPK, PI3K, and JAK/STAT pathways in microglia to influence Alzheimer’s Disease
Zuppe, H. T., & Reed-Geaghan, E. G. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1441691 · Cited by 20 · see citing works
A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome
Sano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065983 · Cited by 16 · see citing works
Yang-Xin-Shu-Mai granule alleviates atherosclerosis by regulating macrophage polarization via the TLR9/MyD88/NF-κB signaling pathway
Huang, H., Sun, Z., Xu, J., Wang, L., Zhao, J., Li, J., Zhang, S., Yuan, F., Liu, M., & Fang, Z. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116868 · Cited by 16 · see citing works
Crafting a Rigorous, Clinically Relevant Large Animal Model of Chronic Myocardial Ischemia: What Have We Learned in 20 Years?
Stone, C. R., Harris, D. D., Broadwin, M., Kanuparthy, M., Sabe, S. A., Xu, C., Feng, J., Abid, M. R., & Sellke, F. W. (2024) · Methods and Protocols · doi:10.3390/mps7010017 · Cited by 16 · see citing works
Markers of inflammation predicts long-term mortality in patients with acute coronary syndrome – a cohort study
Odeberg, J., Halling, A., Ringborn, M., Freitag, M., Persson, M.-L., Vaara, I., Råstam, L., Odeberg, H., & Lindblad, U. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04608-9 · Cited by 16 · see citing works
Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
Mahjoubin‐Tehran, M., Teng, Y., Jalili, A., Aghaee‐Bakhtiari, S. H., Markin, A. M., & Sahebkar, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094420 · Cited by 16 · see citing works
Metabolomics and lipidomics combined with serum pharmacochemistry uncover the potential mechanism of Huang-Lian-Jie-Du decoction alleviates atherosclerosis in ApoE−/− mice
Yang, X., Chi, C., Li, W., Zhang, Y., Yang, S., Xu, R., & Liu, R. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117748 · Cited by 15 · see citing works
The dawn has come for new therapeutics to treat atherosclerosis: Targeting neuroimmune cardiovascular interfaces in artery brain circuits
Mohanta, S. K., Weber, C., Yin, C., & Habenicht, A. J. R. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1040 · Cited by 13 · see citing works
Salvianolic Acid a Attenuates Inflammation-Mediated Atherosclerosis by Suppressing GRP78 Secretion of Endothelial Cells
Fan, X., Zhang, L., La, X., Tian, J., Israr, G., Li, A., Wu, C., An, Y., Li, S., Dong, X., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116219 · Cited by 13 · see citing works
Experimental Agents for the Treatment of Atherosclerosis: New Directions
Voutyritsa, E., Kyriakos, G., Patsouras, A., Damaskos, C., Garmpi, A., Diamantis, E., Garmpis, N., & Savvanis, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265642 · Cited by 7 · see citing works
To Gain Insights into the Pathophysiological Mechanisms of the Thrombo-Inflammatory Process in the Atherosclerotic Plaque
Nappi, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010047 · Cited by 12 · see citing works
BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor
Meibom, D., Wasnaire, P., Beyer, K., Bröhl, A., Cancho‐Grande, Y., Elowe, N. H., Henninger, K., Johannes, S., Jungmann, N. A., Krainz, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02036 · Cited by 12 · see citing works
NLRP3, conveyed via extracellular vesicles from metabolic syndrome patients, is involved in atherosclerosis development
Vidal‐Gómez, X., Vergori, L., Dubois, S. G., Gagnadoux, F., Henni, S., VEERAPEN, R., Meilhac, O., Muñoz, M., Peiró, C., Martínez, M. C., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02296-8 · Cited by 12 · see citing works
Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?
Whayne, T. F. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00408-y · Cited by 12 · see citing works
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 12 · see citing works
Hsp40s play distinct roles during the initial stages of apolipoprotein B biogenesis
Kumari, D., Fisher, E. A., & Brodsky, J. L. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-09-0436 · Cited by 11 · see citing works
Olive mill wastewater and hydroxytyrosol inhibits atherogenesis in apolipoprotein E-deficient mice
Hara, T., Fukuda, D., Ganbaatar, B., Pham, P. T., Aini, K., Rahadian, A., Suto, K., Yagi, S., Kusunose, K., Yamada, H., et al. (2023) · Heart and Vessels · doi:10.1007/s00380-023-02290-5 · Cited by 10 · see citing works
Matrine ameliorates the inflammatory response and lipid metabolism in vascular smooth muscle cells through the NF‑κB pathway
Wang, G., Ji, C., Wang, H., Liu, Z., Qu, A., & Wang, H. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10744 · Cited by 10 · see citing works
RNA interference-based therapies for the control of atherosclerosis risk factors
Kettunen, S., Ruotsalainen, A., & Ylä‐Herttuala, S. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000972 · Cited by 10 · see citing works
Proinflammatory mediators, TNFα, IFNγ, and thrombin, directly induce lymphatic capillary tube regression
Kemp, S. S., Penn, M. R., Koller, G. M., Griffin, C. T., & Davis, G. E. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.937982 · Cited by 9 · see citing works
Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?
Samuel, M., & Waters, D. D. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.06.012 · Cited by 8 · see citing works
Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean
Oh, Y. H., Jeong, S., Park, S. J., Ahn, J. C., & Park, S. M. (2023) · Medicine · doi:10.1097/md.0000000000035804 · Cited by 7 · see citing works
Therapeutic perspectives of extracellular vesicles and extracellular microRNAs in atherosclerosis
Chang, Y., & Wang, K.-C. (2021) · Current topics in membranes · doi:10.1016/bs.ctm.2021.08.005 · Cited by 7 · see citing works
Thymic stromal lymphopoietin is a key cytokine for the immunomodulation of atherogenesis with Freund's adjuvant
Steinmetz, M., Laurans, L., Nordsiek, S., Weiß, L., der Veken, B. V., Ponnuswamy, P., Esposito, B., Vandestienne, M., Giraud, A., Göbbel, C., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15235 · Cited by 6 · see citing works
From remnant cholesterol to lipoprotein(a) – emerging risk factors for cardiovascular diseases beyond low density lipoprotein
Mukherjee, D., & Mikhailidis, D. P. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001142 · Cited by 6 · see citing works
Connecting the Dots: How MicroRNAs Link Asthma and Atherosclerosis
Zimbru, R.-I., Zimbru, E.-L., Bojin, F. M., Haidar, L., Andor, M., Harich, O. O., Tănasie, G., Tatu, C. S., Mailat, D.-E., Zbîrcea, I.-M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083570 · Cited by 5 · see citing works
Hepatic steatosis associates with leukopoietic activity and atherosclerotic inflammation: mechanistic insights into cardiovascular risk
Abohashem, S., Aldosoky, W., Abbasi, T. A., Dar, T. A., Rollings, R. C., Tung, B., Hammad, B., Saeed, F. U., Ali, A., Takx, R. A. P., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156427 · Cited by 5 · see citing works
The Pathophysiological Interrelationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease
Gál, A. R., Szokodi, I., Vizvári, Z., Győrfi, N., Vereczkei, A. G., Petykó, Z., Karádi, Z., & Tóth, A. (2026) · Antioxidants · doi:10.3390/antiox15060710 · Cited by 6 · see citing works
Direct NLRP3 inflammasome inhibitors for cardiovascular therapeutics: a comparative review of synthetic and natural candidates
Zhen, D., Liu, C., Sun, X., Bao, T., Wang, B., Zheng, K., Wu, Z., Chen, X., & Zhang, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1861169 · Cited by 5 · see citing works
Comorbidity of non-alcoholic fatty liver disease and cardiovascular disease: focus on ademetionine and ursodeoxycholic acid
Polyakova, O. A., Ostroumova, O. D., Ковалева, Г. П., & Евгеньевна, П. Е. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-29-13-20 · Cited by 5 · see citing works
Novel functions of Tribbles-homolog 1 in liver, adipocytes and atherosclerosis
Hernandez-Resendiz, I., & Burkhardt, R. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000917 · Cited by 5 · see citing works

Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
Zheng, W. C., Chan, W., Dart, A. M., & Shaw, J. A. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad074 · Cited by 61 · see citing works
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment
d’Aiello, A., Filomia, S., Brecciaroli, M., Sanna, T., Pedicino, D., & Liuzzo, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01241-3 · Cited by 42 · see citing works
Anti-inflammatory Therapy for Cardiovascular Disease
Ridker, P. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00024-8 · Cited by 1 · see citing works
Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis
Hafiane, A., & Daskalopoulou, S. S. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106157 · Cited by 40 · see citing works
Experimental Agents for the Treatment of Atherosclerosis: New Directions
Voutyritsa, E., Kyriakos, G., Patsouras, A., Damaskos, C., Garmpi, A., Diamantis, E., Garmpis, N., & Savvanis, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265642 · Cited by 7 · see citing works

Authors: Libby, P., & Everett, B. M.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Libby, Peter
ORCID: Libby, Peter
Everett, Brendan M.
Venue: Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2019-04
Volume: 39
Issue: 4
Pages: 538-545
ISSN: 1079-5642 (ISSN-L)
1524-4636
DOI: 10.1161/atvbaha.118.310958
PMC: PMC6436984
OpenAlex: W2917926925
Cited by: 145
References: 83
Citations by year: 2026: 11 · 2025: 18 · 2024: 11 · 2023: 18 · 2022: 27 · 2021: 29 · 2020: 20 · 2019: 11
FWCI: 1.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: American Heart Association (18CSA34080399)
National Heart, Lung, and Blood Institute (R01HL080472)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Keywords: atherosclerosis, antiatherosclerotic therapy, residual cardiovascular risk, dyslipidemia, antioxidants, inflammation, p38 MAPK inhibition, P-selectin, methotrexate, colchicine, IL-1β, NLRP3 inflammasome, interleukin-6, secondary prevention, CANTOS trial
MeSH terms: Anti-Inflammatory Agents, Antioxidants, Clinical Trials as Topic, Clone Cells, Hematopoiesis, Humans, Inflammation, Life Style, Risk Factors, Vaccination, Therapies, Investigational, Atherosclerosis, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Novel antiatherosclerotic therapies

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks